Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DAP000842

Drug Information
SynonymsAC1L1D0R; alpha-(p-Aminophenyl)-alpha-ethylglutarimide; HMS2090I05; Prestwick3_000244; Prestwick2_000244; Aminoglutetimida; A1947; Prestwick0_000244; Ba 16038; Cytadren (TN); NCGC00093615-02; KBio1_000884; NCGC00015110-02; KBioSS_000400; (+/-)-p-AMINOGLUTETHIMIDE; Novartis Brand of Aminoglutethimide; BSPBio_001832; HMS1920C09; Prestwick_243; dl-Aminoglutethimide; NCGC00093615-03; Spectrum5_000802; BRD-A25234499-001-05-0; AB00051935; CHEMBL488; STK802074; Spectrum4_000144; CPD000326785; SPBio_002247; Ba-16038; UNII-0O54ZQ14I9; BPBio1_000032; DB00357; CID2145; Aminoglutethimidum; AG-1; CPD-10532; Aminoglutethimide (USP/INN); EINECS 204-756-4; Aminoglutethimidum [INN-Latin]; SAM002589964; NSC330915; AC-12456; NCGC00093615-04; Spectrum3_000296; KBio2_000400; NINDS_000884; SPECTRUM1500115; Lopac0_000124; 2,6-Piperidinedione, 3-(4-aminophenyl)-3-ethyl-; HMS2091I09; C 16038-BA; 3-(4-Aminophenyl)-3-ethyl-2,6-piperidinedione; Aminoglutethimide [INN:BAN]; Glutarimide, 2-(p-aminophenyl)-2-ethyl-; DivK1c_000884; NCGC00093615-05; NCI60_002900; CCRIS 7562; Elipten; Aminoglutetimida [INN-Spanish]; 3-(p-Aminophenyl)-3-ethylpiperidine-2,6-dione; MolPort-001-828-287; D00574; aminoglutethimide; HMS1568B10; MLS000859924; KBio3_001332; SMP1_000017; Glutethimide, para-amino; BB_SC-1153; SPBio_000046; AKOS004120070; 3-Ethyl-3-(p-aminophenyl)-2,6-dioxopiperidine; A 9657; LS-72014; HSDB 7494; CHEBI:2654; KBioGR_000588; 3-(4-Aminophenyl)-3-ethyl-2,6-piperidindion; Spectrum2_000093; Prestwick1_000244; KBio2_002968; C07617; Cytadren; NCGC00015110-07; 2-(p-Aminophenyl)-2-ethylglutarimide; Spectrum_000040; SMR000326785; AC1Q2SPJ; MLS001213216; Ciba Vision Brand of Aminoglutethimide; HMS502M06; KBio2_005536; aminoglutethimide (AG); S1672_Selleck; IDI1_000884; ( inverted question mark)-p-Aminoglutethimide; (+-)-3-(p-Aminophenyl)-3-ethyl-2,6-piperidinedione; .alpha.-(p-Aminophenyl)-.alpha.-ethylglutarimide; BSPBio_000028; p-Aminoglutethimide; 3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione; A9657_SIGMA; NCGC00093615-01; EU-0100124; D000616; Orimeten; BRN 0210656; (?)-p-Aminoglutethimide; VU0243029-3; 125-84-8
Trade NameCytadren
CompanyNorvatis Phamaceuticals Corporation
IndicationCushing's syndrome and metastatic breast cancer
[ICD9: 174, 175, 255.0   ICD10: C50, E24]
Approved    [1]
Cushing's syndrome and metastatic breast cancer
[ICD9: 174, 175, 255.0   ICD10: C50, E24]
Approved    [2]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Canonical SMILESCCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N    
Therapeutic ClassAntineoplastic Agents
CAS NumberCAS 125-84-8
PubChem Compound IDCID 2145.
PubChem Substance IDSID 9819.
SuperDrug ATC IDL02BG01
SuperDrug CAS ID000125848;
Cytochrome P450 11A1Inhibitor[1]
Ref 1Breakdown of Th cell immune responses and steroidogenic CYP11A1 expression in CD4+ T cells in a murine model implanted with B16 melanoma. Cell Immunol. 2000 Nov 25;206(1):7-15. To Reference
Ref 2Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. To Reference
Ref 3Aminoglutethimide-induced protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis. Chem Res Toxicol. 2007 Jul;20(7):1038-45. Epub 2007 Jun 30. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links


Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543